Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes

This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in d...

Full description

Saved in:
Bibliographic Details
Published in:The Pharmacogenomics Journal 2016, Vol.16 (5), p.439
Main Authors: Mas, S, Gassó, P, Lafuente, A, Bioque, M, Lobo, A, Gonzàlez-Pinto, A, Olmeda, M S, Corripio, I, Llerena, A, Cabrera, B, Saiz-Ruiz, J, Bernardo, M, Mezquida, Gisela, Meseguer, Ana, Bernardo, Enrique García, Parellada, Mara, Alonso-Solís, Anna, Grasa, Eva, Hernandez, Miryam, Cengotitabengoa, Monica Ma, Barcones, Fe, Arbej, Julio, Sanjuan, Julio, Aguilar, Eduardo J, Balbuena, Antonio, Mané, Anna, Torrent, Carla, Vieta, Eduard, Baeza, Immaculada, Serna, Elena de la, Contreras, Fernando, Albacete, Auria, García-Po, Bobes, Julio, Zabala Rabadán, Arantzazu, Segarra Echevarría, Rafael, Morales-Muñoz, Isabel, Rodriguez-Jimenez, Roberto, Butjosa, Anna, Usall Rodie, Judith, Sarró, Salvador, Landín-Romero, Ramón, Ibañez Cuadrado, Angela, Cuesta, Manuel J, Balanzá-Martínez, Vicent
Format: Report
Language:English
Subjects:
Antipsychotic agents
Dopamine receptors
Dosage and administration
Drug therapy
Genetic aspects
Glutamate
Serotonin
Single nucleotide polymorphisms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis. The statistical analysis was adjusted by age, gender, AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the risk of EPS after correction for multiple testing (P [less than] 1 x 10[sup.-4]). These findings support the involvement of dopamine, serotonin and glutamate pathways in AP-induced EPS. The Pharmacogenomics Journal (2016) 16, 439-445; doi: 10.1038/tpj.2016.44; published online 7 June 2016
ISSN:1470-269X
DOI:10.1038/tpj.2016.44